Nonprescription Drug Rule Pushed Back to May 2025
Published Date: 3/25/2025
Rule
Summary
The new rule about nonprescription drugs with extra conditions won’t start until May 20, 2025, because the government needs more time to review it. This affects drug makers and sellers who must follow the updated rules once they kick in. No extra costs or fees are mentioned, just a longer wait before the changes take effect.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2025-04971 — Unaccompanied Children Program Foundational Rule; Update To Accord With Statutory Requirements
The government is updating rules about how unaccompanied children in federal custody are cared for and placed, making sure the rules match the law exactly. This affects kids who come to the U.S. alone and the agencies that help them. The changes keep things clear and fair, with no new costs or delays expected.
Next: 2025-05041 — Fisheries of the Exclusive Economic Zone Off Alaska; Reallocation of Pacific Cod in the Bering Sea and Aleutian Islands Management Area
The government is shifting some unused Pacific cod fishing quota from jig gear boats to smaller catcher vessels using hook-and-line or pot gear in the Bering Sea and Aleutian Islands. This change helps make sure the 2025 fishing season’s Pacific cod limits get fully used. Fishermen with boats under 60 feet will benefit from this reallocation starting in the 2025 A season.